m

O

ļ.

جُوطٍ

N

Signature

PTO/SB/05 (11-00)

12/04/01

Date

	-	
1	(-	

Please type a plus sign (+) inside this box —

Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control num

UTILITY PATENT APPLICATION TRANSMITTAL

IOZ01-NP009 Attorney Docket No. Iozzo, Renato V. First Inventor Endorepellin: Methods and Compositions for Inhibiting Angiogenesis

Express Mail Label No. EV044356728US (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages | 38 (preferred arrangement set forth below) a. X Computer Readable Form (CRF) - Descriptive title of the invention Specification Sequence Listing on: - Cross Reference to Related Applications i. CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix c. X Statements verifying identity of above copies Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description 9. X Assignment Papers (cover sheet & document(s)) - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets 22 11. Copies of IDS Information Disclosure 12. 5. Oath or Declaration [Total Pages Citations Statement (IDS)/PTO-1449 13. **Preliminary Amendment** Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** 15 Signed statement attached deleting inventor(s) Request and Certification under 35 U.S.C. 122 named in the prior application, see 37 CFR 16. 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 Other: 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Divisional Continuation Continuation-in-part (CIP) of prior application No.: Prior application information: Examiner Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Label Name Address City State Zip Code Country Telephone Fax Registration No. (Attorney/Agent) 45,461 Janet B. Smith Name (Print/Type)

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES ON COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Passywork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ÉE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

704.00 (\$)

Complete if Known				
Application Number				
Filing Date	12/04/2001			
First Named Inventor	IOZZO, Renato V.			
Examiner Name				
Group Art Unit				
Attorney Docket No.	IOZ01-NP009	7		

	METHOD OF PAYMENT	FEE CALCULATION (continued)					
	1. X The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES					
	Deposit 50 0404	Large Small Entity Entity					
	Account Number 50-0491	,	Fee Paid				
	Account Name Thomas Jefferson University	105 130 205 65 Surcharge - late filing fee or oath					
	Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet					
- 1	X Applicant claims small entity status.	139 130 139 130 Non-English specification					
ŀ	See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination					
ļ4	2. Payment Enclosed: Check Credit card Money Order Other	112 920* 112 920* Requesting publication of SIR prior to Examiner action					
	FEE CALCULATION	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action					
Q ·	1. BASIC FILING FEE	115 110 215 55 Extension for reply within first month					
13.	Large Entity Small Entity	116 400 216 200 Extension for reply within second month					
m	Fee Fee Fee Fee Description	117 920 217 460 Extension for reply within third month					
O	Code (\$) Code (\$) Fee Paid	118 1,440 218 720 Extension for reply within fourth month					
ļ4	101 740 201 370 Utility filing fee 370.00	128 1,960 228 980 Extension for reply within fifth month					
11	106 330 206 165 Design filing fee	119 320 219 160 Notice of Appeal					
Si	107 510 207 255 Plant filing fee	120 320 220 160 Filing a brief in support of an appeal					
14	108 740 208 370 Reissue filing fee	121 280 221 140 Request for oral hearing					
	114 160 214 80 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding					
7	SUBTOTAL (1) (\$) 370.00	140 110 240 55 Petition to revive - unavoidable					
	2. EXTRA CLAIM FEES	141 1,280 241 640 Petition to revive - unintentional					
	Fee from						
12 14	Total Claims 15 -20** = X 9.00 = 0.00	143 460 243 230 Design issue fee					
ži ma	Independent $\begin{bmatrix} 10 \\ -3^{**} = \end{bmatrix} \begin{bmatrix} 7 \\ x \end{bmatrix} \begin{bmatrix} 42 \\ 00 \end{bmatrix} = \begin{bmatrix} 294 \\ 00 \end{bmatrix}$	144 620 244 310 Plant issue fee					
	Claims	122 130 122 130 Petitions to the Commissioner					
		123 50 123 50 Processing fee under 37 CFR 1.17(g)					
	Large Entity Small Entity	126 180 126 180 Submission of Information Disclosure Stmt					
	Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per	40.00				
	103 18 203 9 Claims in excess of 20	property (times number of properties)	+0.00				
	102 84 202 42 Independent claims in excess of 3	146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a))					
	104 280 204 140 Multiple dependent claim, if not paid 109 84 209 42 ** Reissue independent claims	149 740 249 370 For each additional invention to be examined (37 CFR § 1.129(b))					
ı	over original patent 110 18 210 9 ** Reissue claims in excess of 20	179 740 279 370 Request for Continued Examination (RCE)					
	and over original patent	169 900 169 900 Request for expedited examination of a design application					
	SUBTOTAL (2) (\$) 294.00	Other fee (specify)					
	**or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 40.00					

SUBMITTED BY				Complete (ii	Complete (if applicable)	
Name (Print/Type)	Janet B. Smith	Registration No. (Attorney/Agent)	5,461	Telephone	(215) 503-2386	
Signature	Jane & Bothow WK			Date	12/04/2001	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

IOZ01-NP009

TITLE:

Endorepellin: Methods and Compositions for Inhibiting

Angiogenesis

INVENTOR(S):

Iozzo, Renato V.

"Express Mail" Label No. EV0443567283US Date of Deposit – December 4, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Typed Name: Janet B. Smith

Box Patent Application

Commissioner of Patents & Trademarks

Washington, DC 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In <u>re</u> Application : Group Art Unit: Unknown

Iozzo, Renato V., et al. : Examiner: Unknown

.

Serial No.: Unknown : Attorney Docket

IOZ01-NP009

Filed: December 4, 2001 :

For: Endorepellin: Methods and Compositions for Inhibiting Angiogenesis

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825.

- (X) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- (X) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not Include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.
- (X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

DATA SHEET

DOCKET NUMBER:

IOZ01-NP009

FILING TITLE:

Endorepellin: Methods and Compositions for Inhibiting

Angiogenesis

PRIORITY TO BE CLAIMED:

APPLICANT:

THOMAS JEFFERSON UNIVERSITY


1020 Walnut Street Philadelphia, PA 19107 United States of America

INVENTORS:

Iozzo, Renato V.

1334 Beumont Drive Gladwyne, PA 19035

US



Janet B. Smith

Registration No. 45,461

Agent for Applicant

THOMAS JEFFERSON UNIVERSITY

1020 Walnut Street – Suite 630 Philadelphia, PA 19107-5587

Telephone: (215-503-2386) Facsimile: (215-923-3613)

Date: December 4, 2001